Influence of Alcohol on Phosphodiesterase 5 inhibitors Use in Middle- to Old-Aged Men: A Comparative Study of Adverse Events

Sexual Medicine - Tập 7 - Trang 425-432 - 2019
Jong Nyeong Kim1, Jong Jin Oh2, Dong Soo Park1, Young Kwon Hong1, Young Dong Yu1
1Department of Urology, CHA Medical University, College of Medicine, Bundang CHA Hospital, Seongnam, Korea
2Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea

Tóm tắt

Abstract Introduction Some previous studies reported recreational use of phosphodiesterase type 5 (PDE-5) inhibitors by ingesting the medicine with alcohol in patients with erectile dysfunction, but the rate of misuse in general population has never been researched. Aim To investigate the frequency of concomitant alcohol consumption with PDE-5 inhibitors in the general male population. We secondarily analyzed the influence of alcohol on PDE-5 inhibitor. Methods 325 men with erectile dysfunction (age 34–78) who received PDE-5 inhibitors at a single medical institution from January 2016–February 2018 were included in the study. All patients fulfilled a survey questionnaire assessing (i) average alcohol consumption amount, (ii) previous use of PDE-5 inhibitors with alcohol and purpose of concomitant alcohol use, (iii) and background knowledge about PDE-5 inhibitors' side effects. Main Outcomes Measures The main outcome measure was frequency of concomitant alcohol consumption with PDE-5 inhibitors in the general male population. Results Overall 148 patients committed concomitant alcohol use (group 1), and 177 patients did not (group 2). No significant differences were observed between 2 groups regarding types of PDE-5 inhibitors used and underlying disease. Group 2 had significantly more patients with the correct knowledge concerning concomitant alcohol use than group 1 (24.9% vs 13.5%). Group 1 had more patients with average alcohol consumption >15 drinks/week (64.8% vs 14.1%). The reasons for concomitant alcohol use were curiosity (35.1%), enhancing sexual desire (27%) and recommendation from friends (16.9%). Group 1 showed significantly greater complications, including headache (23.6% vs 7.3%) and facial flushing (69.6% vs 12.4%), than group 2. 1 patient in group 1 experienced severe chest discomfort and underwent coronary artery angiography, but no severe obstructive lesion was observed. Conclusion 45.5% of middle- to old-age men committed concomitant use of PDE-5 inhibitor with alcohol because of recreational purpose, and this alcohol abuse might lead to severe complications, including chest discomfort and dizziness.

Tài liệu tham khảo

Anderson, 2017, Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction, Heart, 103, 1264, 10.1136/heartjnl-2016-310746 Korkes, 2008, Recreational use of PDE5 inhibitors by young healthy men: Recognizing this issue among medical students, J Sex Med, 5, 2414 Francis, 2003, Molecular mechanisms and pharmacokinetics of phosphodiesterase 5 antagonists, Curr Urol Rep, 4, 457, 10.1007/s11934-003-0027-x Wang, 2012, Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability: Implications for clinical safety and improved tolerability, J Sex Med, 9, 2122 Aldridge, 1999, Sildenafil (Viagra) is used as a recreational drug in England, BMJ, 318, 669, 10.1136/bmj.318.7184.669 Benotsch, 2006, Substance use, medications for sexual facilitation, and sexual risk behavior among traveling men who have sex with men, Sex Transm Dis, 33, 706, 10.1097/01.olq.0000218862.34644.0e Smith, 2005, Recreational use and misuse of phosphodiesterase 5 inhibitors, J Am Pharm Assoc (Wash DC), 45, 63 Kim, 2002, Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra, San Francisco 2000–2001, AIDS, 16, 1425, 10.1097/00002030-200207050-00017 McCambridge, 2006, The rise of Viagra among British illicit drug users: 5-year survey data, Drug Alcohol Rev, 25, 111, 10.1080/09595230500537167 Acevedo, 2001, Ethanol inhibits L-arginine uptake and enhances NO formation In human placenta, Life SCI, 68, 2893, 10.1016/S0024-3205(01)01070-0 Venkov, 1999, Ethanol Increases endothelial nitric oxide production through modulation of nitric oxide synthase expression, Thromb Haemost, 81, 638, 10.1055/s-0037-1614538 Corbin, 2005, High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors, Biochem Biophys Res Commun, 334, 930, 10.1016/j.bbrc.2005.06.183 Vardi, 2002, Effects of sildenafil citrate (Viagra) on blood pressure In normotensive and hypertensive men, Urology, 59, 747, 10.1016/S0090-4295(02)01510-8 Jeon, 2005, Phosphodiesterase: Overview of protein structures, potential therapeutic applications, and recent progress in drug development, Cell Mol Life Sci, 62, 1198, 10.1007/s00018-005-4533-5 Wensing, 2006, Simultaneous administration of vardenafil and alcohol does not result in a pharmacodynamic or pharmacokinetic interaction in healthy male subjects, Int J Clin Pharmacol Ther, 44, 216, 10.5414/CPP44216 Kim, 2009, Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: A single-dose randomized sequence, open-label, crossover study in healthy male volunteers in Korea, ClinTher, 31, 1234 2014, Global status report on alcohol and health 2014, 290 Alwaal, 2011, Future prospects in the treatment of erectile dysfunction: Focus on avanafil, Drug Des Devel Ther, 5, 435 Limin, 2010, Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction, Expert Opin Investig Drugs, 19, a1427, 10.1517/13543784.2010.518955 Hakky, 2015, Current use of phosphodiesterase inhibitors in urology, Turk J Urol, 41, 88, 10.5152/tud.2015.46354 Musacchio, 2006, Erectile dysfunction and Viagra use: What’s up with college age males?, J Adolesc Health, 39, 452, 10.1016/j.jadohealth.2005.12.021 Carson, 2003, Long-term use of sildenafil, Expert Opin Pharmacother, 4, 397, 10.1517/14656566.4.3.397 Carson, 2002, The efficacy of Sildenafil citrate (Viagra) in patients with erectile dysfunction, Urology, 60, 12, 10.1016/S0090-4295(02)01687-4 Carson, 2002, Sildenafil citrate treatment for erectile dysfunction: Rate of adverse events decreases with time, J Urol, 167, 179 McMahon, 2005, Comparison of efficacy, safety, and tolerability of on-demand Tadalafil and daily dosed Tadalafil for the treatment of erectile dysfunction, J Sex Med, 2, 415 Marmor, 1999, Sildenafil and ophthalmology, Surv Ophthalmol, 44, 153, 10.1016/S0039-6257(99)00079-X Thurtell, 2008, Non-arteritic ischemic optic neuropathy with PDE5 inhibitors for erectile dysfunction, Int J Impot Res, 20, 537, 10.1038/ijir.2008.25 Hellstrom, 2002, Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial, J Androl, 23, 763 Manfroi, 2003, Hemodynamic effects of sildenafil in patients with stable ischemic heart disease, Int J Cardiol, 90, 153, 10.1016/S0167-5273(02)00418-7 Shin, 2017, Alcohol consumption, aldehyde dehydrogenase 2 gene polymorphisms, and cardiovascular health in Korea, Yonsei Med J, 58, 689, 10.3349/ymj.2017.58.4.689
Thông tin
Thông tin xuất bản

Sexual Medicine

Tập 7

425-432

Thông tin tác giả